A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM
Condition(s):Multiple Myeloma in Relapse; Multiple Myeloma; Multiple Myeloma of Bone; Multiple Myeloma With Failed RemissionLast Updated:September 29, 2023Active, not recruiting